Oriola-KD makes changes to management team

Henry Fogels adds acting director general of wholesale business in Russia to his duties

Henry Fogels, general director of Oriola-KD's Pharmaceutical Retail business in Russia (OOO Vitim) has been nominated, in addition to his current duties, to the position of acting general director of Oriola-KD's Pharmaceutical Wholesale business in Russia.

Fogels will continue as a member of Oriola-KD's Group Management Team, being responsible for Oriola-KD's businesses in Russia.

Fogels has replaced Vladimir Knyazev, who left the Espoo, Finland-based company this month.

You may also like

Manufacturing

Oriola-KD to sell healthcare trade business to Mediq

Dutch firm to acquire Oriola-KD businesses across Scandinavia and Europe
Regulatory

Standard proposed to clarify endotoxin testing for single-use systems

The guide will address variability when assessing bacterial endotoxins on large-scale pharmaceutical equipment
Research & Development

Weight loss drugs such as Ozempic may prevent stroke and reduce brain injury related complications

Three studies presented at the Society of NeuroInterventional Surgery's (SNIS) 22nd Annual Meeting discussed whether using GLP-1 inhibitors could lessen the impacts of stroke and related brain injuries or reduce the risk of stroke altogether
Finance

Sanofi completes acquisition of Blueprint Medicines

Sanofi announces the completion of its acquisition of Blueprint Medicines Corporation, adding to its portfolio a commercialised medicine and the expertise of a company specialising in systemic mastocytosis (SM) and other KIT-driven diseases
Personal Protection

Almost 60% of workplace injuries from harmful substances are burns

Chemical burns continue to be the leading type of non-fatal injury caused by exposure to or contact with harmful substances in workplaces across Great Britain
Regulatory

AlzeCure's pain project ACD440 granted orphan drug status in the US by the FDA

AlzeCure Pharma announces that the US Food and Drug Administration (FDA) has granted the company's application for orphan drug status for the clinical pain candidate drug ACD440
Finance

Evestia Clinical to merge with Atlantic Research Group

The merger delivers on Evestia Clinical’s strategy of targeted growth through the expansion of services, enhanced technology and broadened geographical reach
Subscribe now